Scholarlink

Objective <p>Malignant rhabdoid tumor of the kidney (MRTK) is a rare and highly aggressive pediatric malignancy with a poor prognosis. We report a rare case of acute myeloid leukemia (AML) developing after successful treatment of MRTK in a child and discuss its clinical course and possible therapy-related etiology.</p> Case presentation <p>We successfully treated a 12-year-old Iranian girl of Turkish ethnicity with stage III or higher MRTK in Qazvin, Iran, using surgery, chemotherapy, and radiotherapy. Approximately 7 months after completion of chemotherapy and radiotherapy, and 16 months after the initial diagnosis of MRTK, the patient developed acute myeloid leukemia.</p> Conclusion <p>This case highlights the development of acute myeloid leukemia after treatment for malignant rhabdoid tumor of the kidney in a pediatric patient. Long-term follow-up is essential for the early detection of secondary malignancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acute myeloid leukemia following treatment of malignant rhabdoid tumor of the kidney: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月11日

查看全文
  • Majid Vafaie,
  • Elahe Jafari,
  • Manoochehr Mahram

摘要

Objective

Malignant rhabdoid tumor of the kidney (MRTK) is a rare and highly aggressive pediatric malignancy with a poor prognosis. We report a rare case of acute myeloid leukemia (AML) developing after successful treatment of MRTK in a child and discuss its clinical course and possible therapy-related etiology.

Case presentation

We successfully treated a 12-year-old Iranian girl of Turkish ethnicity with stage III or higher MRTK in Qazvin, Iran, using surgery, chemotherapy, and radiotherapy. Approximately 7 months after completion of chemotherapy and radiotherapy, and 16 months after the initial diagnosis of MRTK, the patient developed acute myeloid leukemia.

Conclusion

This case highlights the development of acute myeloid leukemia after treatment for malignant rhabdoid tumor of the kidney in a pediatric patient. Long-term follow-up is essential for the early detection of secondary malignancies.